Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of lovastatin
Inhibitors and simvastatin; thereby, increasing the risk of
myopathy including rhabdomyolysis (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
36
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of lovastatin
Inhibitors and simvastatin; thereby, increasing the risk of
myopathy including rhabdomyolysis (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism,
Pravastatin, Rosuvastatin, Simvastatin such as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent
or as a pharmacokinetic enhancer. Since increased concentrations of lovastatin and
simvastatin may predispose patients to myopathies, including rhabdomyolysis, the
combination of these medicinal products with ritonavir is contraindicated (see
section 4.3). Atorvastatin is less dependent on CYP3A for metabolism. While
rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin
exposure has been reported with ritonavir co-administration. The mechanism of this
interaction is not clear, but may be the result of transporter inhibition. When used
with ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent, the
lowest possible doses of atorvastatin or rosuvastatin should be administered. The
metabolism of pravastatin and fluvastatin is not dependent on CYP3A, and
interactions are not expected with ritonavir. If treatment with an HMG-CoA
reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
HMG Co-A Reductase
Inhibitors
Atorvastatin, Fluvastatin, Lovastatin, HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such
Pravstatin, Rosuvastatin, Simvastatin as lovastatin and simvastatin, are expected to have markedly increased plasma
concentrations when co-administered with ritonavir dosed as an antiretroviral agent or as
a pharmacokinetic enhancer. Since increased concentrations of lovastatin and simvastatin
may predispose patients to myopathies, including rhabdomyolysis, the combination of
these medicinal products with ritonavir is contraindicated (see section 4.3). Atorvastatin
is less dependent on CYP3A for metabolism. While rosuvastatin elimination is not
dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with
ritonavir co-administration. The mechanism of this interaction is not clear, but may be
the result of transporter inhibition. When used with ritonavir dosed as a pharmacokinetic
enhancer or as an antiretroviral agent, the lowest possible doses of atorvastatin or
rosuvastatin should be administered. The metabolism of pravastatin and fluvastatin is not
dependent on CYP3A, and interactions are not expected with ritonavir. If treatment with
an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage aecf6db95f104726bea3f53130826841fcecb464a1fff5ff24afdad33e090079 · Zeichen 44359–46167 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.